HALOZYME THERAPEUTICS AND BAXTER HEALTHCARE CORPORATION EXPAND RELATIONSHIP TO INCLUDE EU

Halozyme Therapeutics, Inc., a biopharmaceutical company focused on the development and commercialization of recombinant human enzymes, and Baxter Healthcare Corporation (Baxter) announced today that Baxter has exercised its option to market, sell, and distribute Hylenex(TM) in the European Union. Hylenex is a local formulation of recombinant human hyaluronidase under development for use as a "spreading agent" to enhance the delivery of local anesthesia, contrast agents, and for subcutaneous fluid replacement (also called hypodermoclysis).

Finanzen.net (http://finanzen.net/news/news_detail.asp?NewsNr=325714)